Roche chases bolt-on acquisitions as it pushes into genomics

A recent spending spree by Roche is intended to take advantage of emerging molecular information and genomic analysis, as the company anticipates that the field will play an increasingly important role for future medicines and diagnostics. 'By harnessing the power of widespread whole genome sequencing, we are hoping to gain valuable insights into new targets, pathways and biomarkers to advance the progress of personalised treatments,' says Roche spokeswoman Nadine Pinell.

http://ift.tt/1zxlOYh